HC Wainwright Reiterates Buy Rating for Milestone Pharmaceuticals (NASDAQ:MIST)

Milestone Pharmaceuticals (NASDAQ:MIST)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a note issued to investors on Thursday, Benzinga reports.

Other equities analysts also recently issued reports about the company. Cantor Fitzgerald initiated coverage on Milestone Pharmaceuticals in a research report on Thursday, August 20th. They issued an “overweight” rating and a $3.00 price objective on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a research report on Tuesday, July 14th. Wells Fargo & Company reduced their price target on shares of Milestone Pharmaceuticals from $8.00 to $7.00 and set an “overweight” rating for the company in a research report on Thursday, May 14th. Wall Street Zen downgraded Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Sunday, May 17th. Finally, Zacks Research raised shares of Milestone Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $6.40.

Milestone Pharmaceuticals Price Performance

Shares of Milestone Pharmaceuticals stock traded up $0.04 during trading on Thursday, hitting $1.23. 1,295,656 shares of the stock traded hands, compared to its average volume of 1,863,977. The stock has a market cap of $152.51 million, a price-to-earnings ratio of -1.78 and a beta of 0.98. The company has a quick ratio of 7.92, a current ratio of 8.13 and a debt-to-equity ratio of 3.25. Milestone Pharmaceuticals has a 52 week low of $1.00 and a 52 week high of $3.06. The firm’s fifty day moving average is $1.19 and its 200-day moving average is $1.45.

Milestone Pharmaceuticals (NASDAQ:MIST) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). The firm had revenue of $0.56 million for the quarter, compared to the consensus estimate of $0.82 million. Research analysts expect that Milestone Pharmaceuticals will post -0.84 EPS for the current fiscal year.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. HighTower Advisors LLC lifted its stake in Milestone Pharmaceuticals by 100.0% in the second quarter. HighTower Advisors LLC now owns 20,000 shares of the company’s stock worth $27,000 after acquiring an additional 10,000 shares during the last quarter. Creative Planning raised its stake in Milestone Pharmaceuticals by 74.6% in the second quarter. Creative Planning now owns 23,410 shares of the company’s stock valued at $45,000 after buying an additional 10,000 shares in the last quarter. Raymond James Financial Inc. lifted its holdings in Milestone Pharmaceuticals by 30.1% during the 2nd quarter. Raymond James Financial Inc. now owns 43,235 shares of the company’s stock worth $84,000 after buying an additional 10,000 shares during the last quarter. Strategic Family Wealth Counselors L.L.C. purchased a new position in shares of Milestone Pharmaceuticals in the 4th quarter valued at about $25,000. Finally, Eaton Financial Holdings Company LLC acquired a new position in Milestone Pharmaceuticals in the fourth quarter valued at approximately $26,000. Institutional investors and hedge funds own 86.18% of the company’s stock.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.